WHAT IS CLAIMED IS:

1. A method for inhibiting a condition characterized by monocytic infiltrates, wherein said method comprises administering to a patient a therapeutically effective amount of an MCP-1 receptor antagonist in a suitable pharmaceutical carrier, wherein said MCP-1 receptor antagonist binds to an MCP-1 receptor polypeptide.

2. The method of claim 1, wherein said MCP-1 receptor polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

3. The method of claim 1, wherein said MCP-1 receptor antagonist is administered to said patient as a pharmaceutical composition.

4. The method of claim 3, wherein said pharmaceutical composition contains about 10 μg/ml to about 1 mg/ml of the antagonist.

5. The method of claim 1, wherein said antagonist is an antibody or binding fragment thereof.

6. The method of claim 5, wherein said antibody or binding fragment thereof is administered to said patient as a pharmaceutical composition.

7. The method of claim 5, wherein said antibody is a monoclonal antibody.

8. The method of claim 5, wherein said antibody is a humanized antibody.

9. The method of claim 1, wherein said condition is atherosclerosis.

10. A method for inhibiting MCP-1 receptor polypeptide, wherein said method comprises administering to a patient a therapeutically effective amount of an MCP-1 receptor antagonist in a suitable pharmaceutical carrier, wherein said MCP-1 receptor antagonist binds to said MCP-1 receptor polypeptide.

11. The method of claim 10, wherein said MCP-1 receptor polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

12. The method of claim 10, wherein said MCP-1 receptor antagonist is administered to said patient as a pharmaceutical composition.

13. The method of claim 12, wherein said pharmaceutical composition contains about 10 μg/ml to about 1 mg/ml of the antagonist.

14. The method of claim 10, wherein said antagonist is an antibody or binding fragment thereof.

15. The method of claim 14, wherein said antibody or binding fragment thereof is administered to said patient as a pharmaceutical composition.

16. The method of claim 14, wherein said antibody is a monoclonal antibody.

17. The method of claim 14, wherein said antibody is a humanized antibody.